Resting CD4+ T Cells with CD38+CD62L+ Produce Interleukin-4 Which Contributes to Enhanced Replication of T-Tropic Human Immunodeficiency Virus Type 1  by Horikoshi, Haruko et al.
Virology 293, 94–102 (2002)Resting CD4 T Cells with CD38CD62L Produce Interleukin-4 Which Contributes to
Enhanced Replication of T-Tropic Human Immunodeficiency Virus Type 1
Haruko Horikoshi,* Masanobu Kinomoto,* Takeshi Kurosu,* Satoshi Komoto,* Miki Shiraga,* Toru Otake,†
Tetsu Mukai,* and Kazuyoshi Ikuta*,1
*Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan; and
†Department of Virology, Osaka Prefectural Institute of Public Health, Higashinari-ku, Osaka 537-0025, Japan
Received April 10, 2001; returned to author for revision June 28, 2001; accepted October 24, 2001
A significant increase in the CD38 population among T lymphocytes has been observed in human immunodeficiency virus
type 1 (HIV-1)-infected carriers. We previously reported a higher replication rate of T-tropic HIV-1 in the CD4CD38CD62L
than CD38 subset under conditions of mitogen stimulation after infection. Here, we revealed a similarly high susceptibility
in the CD38 subset on culture with conditioned medium containing Th2 cytokine, interleukin (IL)-4 that was produced
endogenously from this subset on stimulation with mitogen or anti-CD3 antibody for 3 days. The contribution of IL-4 to the
upregulated production of virus in the CD38 subset was confirmed by culture of this subset with recombinant human IL-4.
In contrast, the rate of replication in the CD38 subset was not augmented in the conditioned medium from either subset or
with IL-4. However, there were no differences in the surface expression of IL-4 receptor or HIV-1 receptors CD4 and CXCR4
between the two subsets. Thus, the CD4CD38CD62L subset comprises a specific cell population secreting endogenousINTRODUCTION
Disease progression after infection with human immu-
nodeficiency virus type 1 (HIV-1) is well correlated with
virus burden (Cao et al., 1995; Michael et al., 1995). Most
of the HIV-1 in plasma is thought to be produced by
newly infected CD4 T cells and there is a daily HIV-1-
infected vs healthy CD4 T cell replacement war occur-
ring in the patients, so that infected, dying cells contin-
ually are replaced (Ho et al., 1995; Wei et al., 1995; Coffin,
1996; Perelson et al., 1996, 1997). This indicates that
there may be a larger number of newly generating T cells
in individuals at a more progressive stage of the disease.
The  chemokine receptor 5 (CCR5) and chemokine
receptor 4 (CXCR4) are the two major coreceptors for
infection by primary isolates, i.e., most of the primary
isolates obtained from asymptomatic carriers are mono-
cyte/macrophage (M)-tropic and use CCR5 (referred to
as R5 virus), while most isolates from AIDS patients are
T-tropic and use CXCR4 (referred to as X4 virus) (Feng et
al., 1996; Alkhatib et al., 1996; Choe et al., 1996; Deng et
al., 1996; Doranz et al., 1996; Dragic et al., 1996; Bleul et
al., 1997).
Host factors have been known for some time to alter
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94the rate of HIV-1 progression in individuals, including
secretion of cytokines, e.g., proinflammatory cytokines
such as tumor necrosis factor-, interleukin (IL)-1, and
IL-6 upregulate HIV-1 replication, while transforming
growth factor  and IL-10 downregulate HIV-1 replication
(Poli et al., 1990, 1994; Fauci, 1993; Vyakarnam et al.,
1990). In addition, recent studies have indicated that
cytokines involved in the differentiation of immune cells
also play a significant role in controlling HIV-1 replica-
tion, e.g., T-helper type 2 (Th2-type) cytokines enhance
X4 HIV-1 production but also have an inhibitory effect on
R5 HIV-1 production, while Th1 cytokine has completely
the opposite effect on both types of HIV-1 (Salgame et al.,
1998; Galli et al., 1998; Wang et al., 1998; Suzuki et al.,
1999). This difference may partly correlate with differen-
tial regulation of CCR5 and CXCR4 by Th1 and Th2
cytokines in CD4 T cells, e.g., Th1 cytokines upregulate
CCR5 (Patterson et al., 1999) and downregulate CXCR4
(Galli et al., 1998), while Th2 cytokines upregulate CXCR4
(Valentin et al., 1998; Wang et al., 1998; Patterson et al.,
1999; Suzuki et al., 1999) and downregulate CCR5 (Patter-
son et al., 1999). Furthermore, several reports have noted
that in vitro stimulated peripheral blood mononuclear
cells (PBMCs) and cloned T cells derived from HIV-1-
infected individuals at early stages preferentially pro-
duce Th1-type cytokines, whereas cells derived from
HIV-1-infected patients at late stages preferentially se-Th2 cytokine that contributes to the efficient production of
life cycle, probably after the adsorption step. © 2002 Elsevie
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crete Th2-type cytokines (Maggi et al., 1987; Clerici et al.,
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in HIV-1 susceptibility between Th1 and Th2 subsets
prepared after stimulation with Th1 and Th2 cytokines,
respectively, i.e., a higher susceptibility of Th1 cells to R5
HIV-1 (Maggi et al., 1994; Vyakarnam et al., 1995; Suzuki
et al., 1999), and of Th2 cells to X4 HIV-1 (Suzuki et al.,
1999). Thus, Th1 and Th2 cytokines seem to play a key
role in the susceptibility or productivity of R5 and X4
HIV-1, respectively.
In a previous report, we compared the replication rates
of X4 and R5 HIV-1 in the resting CD4 T cells, i.e., CD4
CD38 subsets as well as CD4 naive/memory subsets
(Horikoshi et al., 2001). In the cultures, the cells were
infected and then treated with phytohemagglutinin (PHA)
for 3 days. The results showed that production of X4
HIV-1 was much higher in the CD38 than CD38 subset.
On the other hand, there was no apparent difference in
X4 HIV-1 production between naive and memory sub-
sets. There were no apparent differences in CD4 and
CXCR4 levels between CD38 and CD38 as well as
naive and memory subsets, suggesting that the greater
susceptibility of the CD38 subset to X4 HIV-1 is not
related to the expression levels of HIV-1 receptor or
coreceptor. In contrast, production of R5 HIV-1 was much
higher in CD38 and memory than CD38 and naive
subsets. This seems to be reasonable, because the
CCR5 population was seen predominantly in
CD4CD38 and memory subsets.
CD38 was reported to be expressed on T cells during
the early and terminal stages of differentiation, but not
during intermediate stages (Tedder et al., 1984, 1985;
Salazar-Gonzalez et al., 1985; Do¨rken et al., 1989), al-
though it has been considered to be one of the T cell
activation marker antigens along with CD25 and human
leukocyte antigen (HLA)-DR (Janossy et al., 1992;
Kestens et al., 1992, 1994; Mahalingam et al., 1995; Yagi
et al., 1992). Therefore, this increase of CD38 T cell
population may be due to the increase of newly gener-
ating cells in infected individuals. In our previous study,
CD38 was also expressed on about half of the CD4 T
cells from healthy donor-derived PBMCs, greatly differ-
ent from the value of a few percentages obtained for
activation marker antigens such as CD25 and HLA-DR
(Horikoshi et al., 2001). In addition, most of our
CD4CD38 subset preparations also expressed CD62L
and well overlapped with CD4 T cells in CD45RA ex-
pression (Horikoshi et al., 2001).
In this report, we have focused on the mechanism of
the increase in X4 HIV-1 productivity in CD4CD38
compared to CD4CD38 T cells. The secretion levels of
Th2 cytokine after stimulation with PHA or anti-CD3
monoclonal antibody (MAb) were significantly higher in
the CD38 than CD38 subset in all preparations from
healthy donors. In fact, exogenously added IL-4 signifi-
cantly increased the X4 HIV-1 productivity only in the
CD38 subset. Thus, stimulation of the CD4CD38 sub-
set with mitogen or anti-CD3 antibodies produces a
specific cell population secreting Th2 cytokine that con-
tributes to efficient replication of X4 HIV-1.
RESULTS
Higher susceptibility of the resting CD4CD38 than
CD4CD38 subset to X4 HIV-1
We previously showed that the CD38 subset among
CD4 T cells was more susceptible to a laboratory strain
of X4 HIV-1 (LAI) than the CD38 subset (Horikoshi et al.,
2001). In the cultures, the CD38 subsets at resting stage
were infected and then stimulated with PHA for 3 days.
Therefore, we now compared the HIV-1 susceptibility
between the CD38 subsets that were stimulated with
PHA for 3 days before and after infection with the LAI
strain.
The resting CD4 T cell fraction (99% in CD3; 95% in
CD4; 0.5% in CD8; 0.1% in CD25; 0.5% in CD19; and
0.5% in CD14) prepared from the pooled blood of three
healthy donors was separated into two subsets (CD38
and CD38). Both these subsets were certified to be
negative (0.1%) for CD25. The whole CD4 cell fraction
and CD38 subsets were similarly infected with HIV-1 LAI
strain. After adsorption for 1 h, the cells were incubated
in the presence of PHA for 3 days. As shown in Fig. 1A,
viable cell numbers for LAI infection were similar to
those for mock infection. The viral production rates were
significantly higher in the CD38 than CD38 subset on
infection with LAI, as shown by p24 antigen-capture
enzyme-linked immunosorbent assay (ELISA) of the cul-
ture media (Fig. 1A). Under the same culture conditions,
similarly higher susceptibility of CD38 than CD38 sub-
set was also confirmed by infection with X4-type primary
isolates (17-3-6 and 0-4-26) (data not shown). On the
other hand, there was no difference of the susceptibility
to LAI infection between CD38 subsets when we in-
fected after PHA treatment for 3 days (Fig. 1B). The same
two CD38 subsets from healthy donors were pretreated
with PHA for 3 days and then infected with LAI. In this
case, the viable cell numbers as well as viral production
rates in medium were almost the same between the
CD38 and CD38 subsets.
Predetermination of the CD38 subset to secrete Th2
cytokine that contributes to efficient replication of X4
HIV-1
A clear difference in the susceptibility to X4 HIV-1 was
observed in the CD38 subsets at the resting stage (Fig.
1A), but not in the cells already activated by stimulation
with PHA (Fig. 1B). This may suggest that some soluble
factor(s) responsible for X4 HIV-1 production was se-
creted from the CD38 subset during PHA treatment for
3 days. To test this hypothesis, we next examined the
effect on HIV-1 production of the conditioned media from
the two subsets that had been stimulated with PHA for 3
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days. The subsets prepared as above were similarly
adsorbed with LAI for 1 h and were then cultured as
described in Fig. 1A in the presence of the conditioned
media from the subsets in place of PHA. As shown in Fig.
2, an apparent increase in HIV-1 production was ob-
served in the CD38 subset on treatment with the con-
ditioned medium from the PHA-treated CD38 but not
CD38 subset. The conditioned medium from PHA-
treated CD38 cells also had only a slight effect to
increase virus production in the CD38 subset. The via-
ble cell count was almost the same between the subsets
throughout the infection. Thus, some soluble factor(s)
from the CD38 subset could contribute to the suscep-
tibility of this subset to LAI infection.
There have been reports that the susceptibilities of
CD4 T cells to X4 and R5 HIV-1 were significantly
increased by treatment with Th2 and Th1 cytokines,
respectively (Salgame et al., 1998; Galli et al., 1998; Wang
et al., 1998; Suzuki et al., 1999). Therefore, we next
estimated the amounts of such cytokines in the condi-
tioned media used in Fig. 2 by ELISA. As representatives
of Th1 and Th2 cytokines, we selected IFN- and IL-4,
respectively. As summarized in Table 1, the conditioned
media examined were obtained by the culture of CD38
and CD38 subsets derived from the blood of a single
donor or pooled blood from two or three donors including
the samples from Fig. 2. Unexceptionally, the CD38
subset secreted more IL-4 than the CD38 subset after
stimulation with PHA or anti-CD3 MAb. Although the IL-4
levels were greatly variable among individual samples,
there was no apparent difference between the stimula-
tion with PHA and anti-CD3 MAb in the IL-4 secretion
levels from CD38 subset. In addition, the whole CD4 T
cell fraction showed intermediate values in most cases.
In contrast, the CD38 subset showed a tendency to
secrete larger amounts of IFN- in most cases (five of
eight trials) than the CD38 subset, with some excep-
tions especially in the samples producing higher levels
of this cytokine.
Further, when we examined the amounts of IL-4 in the
conditioned media obtained from both subset cultures
after LAI infection, which were the same as in Fig. 1A, it
was found that this cytokine was secreted more effi-
ciently from the CD38 than CD38 subset or whole
CD4 T cell fraction (data not shown). In addition, it was
found that IL-4 was secreted from the CD38 subset only
in the first 3 days of incubation with PHA and not signif-
icantly in the conditioned media in subsequent cultures.
FIG. 1. Susceptibility of CD38 subsets to T-tropic HIV-1. (A) The CD38 subsets (F, CD4CD38; E, CD4CD38) and whole CD4 T cells ( )
prepared as described under Materials and Methods were mock-infected or infected with LAI at 300 ng/ml for 1 h (corresponding to day 0 in figure)
and then stimulated with PHA for 3 days. Subsequently, cultures were continued for 33 days after infection. The cells were replenished with fresh
medium every 3 days. Cell density was adjusted to 1  106/ml at the time of the replenishment. (B) The same CD38 subsets (F, CD4CD38; E,
CD4CD38) were prestimulated with PHA for 3 days and then similarly infected with HIV-1 LAI (corresponding to day 0 in the figures). The cells were
cultured for a further 9 days with replacement of the medium every 3 days. Kinetics on viable cell numbers and estimates of Gag p24 in individual
culture medium are shown.
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Thus, the higher susceptibility of the CD38 subset to X4
HIV-1 could be due to the endogenous production of Th2
cytokine. To test this possibility, the HIV-1 production in
this subset was further examined on addition of exoge-
nous IL-4.
The CD38 subsets as well as whole CD4 T cell
fraction prepared from the same donors were infected
with LAI for 1 h. The cells were then washed, cultured at
2  106/ml in the presence or absence of 10 ng/ml of
recombinant human IL-4 for 3 days, and cultured again
without IL-4 for a further 30 days. The cell concentration
was adjusted to 1  106/ml in fresh medium every 3
days. As shown in Fig. 3, the viable cell count was similar
in all these populations until 9 days postinfection in both
mock-infected and infected cultures in the absence or
presence of IL-4. Thereafter, the number of viable cells
gradually decreased in the CD38 subset, especially in
the absence of IL-4. After LAI infection, the viable cell
count gradually decreased in the CD38 subset and the
whole CD4 T cell fraction even in the cultures with IL-4.
HIV-1 production in the cultured medium as determined
by p24 antigen-capture ELISA was not apparent in either
FIG. 2. Higher production of HIV-1 from the CD4CD38 than CD4CD38 subset on incubation with the conditioned medium from the
PHA-stimulated CD4CD38 subset. CD38 subsets (F, CD4CD38; E, CD4CD38) were infected with LAI at 300 ng/ml for 1 h and then cultured
with the conditioned medium from CD4CD38 and CD4CD38 subsets (38 CM and 38 CM, respectively). Subsequently, the cells were cultured
until day 33 after infection with replacement of the medium every 3 days. Kinetics on viable cell numbers and estimates of Gag p24 in individual culture
medium are shown.
TABLE 1
Th1 and Th2 Cytokine Production Rates of CD4CD38 and CD4CD38 Subsets
Donor Stimulation
IL-4 production (pg/ml) IFN- production (pg/ml)
CD4 CD4CD38 CD4CD38 CD4 CD4CD38 CD4CD38
Single donor
No. 1 PHAa 0.14 0.21 0.1 189.03 96.37 174.15
No. 2 PHAa 2.05 3.27 0.1 54.00 63.42 100.71
No. 3 PHAa 0.13 1.08 0.11 357.96 521.80 237.43
No. 4 anti-CD3b NDd 16.97 1.62 ND 163.75 465.59
Two donors
No. 1 anti-CD3b 0.47 4.33 2.13 2082.09 601.13 570.10
No. 2 anti-CD3b ND 20.93 2.71 ND 1745.92 713.62
No. 3 anti-CD3b ND 11.72 5.14 ND 242.31 943.65
Three donors
No. 1 PHAa,c 0.48 1.03 0.33 103.89 22.15 66.69
a Cultures with IL-2 at 50 u/ml.
b Cultures with IL-2 at 100 u/ml.
c The same cell cultures used in Fig. 2.
d Not determined.
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subset without IL-4, while production greatly increased
in the CD38 compared to CD38 subset in the presence
of IL-4. The CD4 T cell fraction produced HIV-1 at an
intermediate rate. Flow cytometry of these infected sub-
sets confirmed the higher susceptibility of CD38 than
CD38 to LAI infection, as evidenced by expression of
HIV-1 antigens on most of the cells from CD38 but not
from CD38 which were cultured with IL-4 (Fig. 4).
No apparent differences in the expression of IL-4
receptor as well as HIV-1 receptors CD4 and CXCR4
between CD38 subsets
Possible differences in the surface expression of the
IL-4 receptor as well as HIV-1 receptors were examined
between the two subsets to understand the mechanism
behind the difference in susceptibility to X4 HIV-1. Whole
CD4 T cell fractions from three donors were indepen-
dently analyzed without culture for IL-4 receptor by two-
color flow cytometry, i.e., fluorescein isothiocyanate
(FITC)-IL-4 and phycoerythrin (PE)-CD38 MAb. The re-
sults showed that there was no apparent difference in
the percentage of IL-4 receptor-positive cells between
the CD38 subsets, i.e., positive for IL-4 receptor on 43–
78% of CD38 and 61–78% of CD38 subset (Fig. 5A).
Further, we analyzed this point by single staining of
purified CD4CD38 and CD4CD38 subsets with bi-
otin-IL-4 followed by the FITC-avidine. There was also no
difference in their FITC intensity between the surfaces of
purified CD38 subsets (Fig. 5B). In addition, the CD38
subsets after stimulation with PHA or IL-4 for 3 days as
in Fig. 1A or Fig. 3, respectively, were subjected to flow
cytometry to compare the cell surface expression levels
of CD4 and CXCR4 (Fig. 6). Again, the results showed no
apparent differences between the two subsets in recep-
tor expression.
DISCUSSION
The susceptibility of the CD4CD38 subset to T-
tropic laboratory strain LAI was shown to be much
higher than that of the CD4CD38 subset in our previ-
ous study (Horikoshi et al., 2001). This result was also
confirmed by infection with primary isolates with T-tro-
FIG. 3. Increase of HIV-1 production in the CD4CD38 subset on
stimulation with IL-4. CD38 subsets (F, CD4CD38; E, CD4CD38)
and whole CD4 T cells ( ) were mock-infected or infected with LAI at
300 ng/ml for 1 h and then stimulated with IL-4 in place of PHA for 3
days. Subsequently, the cells were cultured until day 33 after infection
with replacement of the medium every 3 days. Viable cell numbers and
virus production rates are shown.
FIG. 4. Expression of HIV-1 antigens on most of the CD4CD38
cells after T-tropic HIV-1 infection followed by culture with IL-4. The
CD38 subsets and whole CD4 T cells mock-infected (---) and infected
with LAI (O) and cultured for 15 days, which were used in Fig. 3, were
subjected to flow cytometry with the serum from a seropositive indi-
vidual.
FIG. 5. No apparent difference of IL-4 receptor expression between
CD4CD38 and CD4CD38 subsets. CD4 T cells from three donors
were reacted with FITC-IL4 and then with PE-CD38 MAb (A). In (B),
CD4CD38 and CD4CD38 subsets from a single donor were re-
acted with biotin-IL-4 followed by the FITC-avidine (O) and negative
control reagent in the kit (---).
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pism (data not shown). To understand the mechanism for
this difference, we examined the effect of cytokines. The
results clearly showed that (1) the CD38 subset is
predestined to become the specific population with effi-
cient secretion of Th2 cytokine, when the cells were
stimulated with PHA or anti-CD3 MAb; and (2) Th2 cyto-
kine endogenously secreted from the CD38 subset
plays a significant role in the efficient production of X4
HIV-1 in this subset.
A difference between the two subsets in the suscep-
tibility to X4 HIV-1 was observed in the cultures on
infection followed by PHA stimulation for 3 days. How-
ever, we could not detect any difference in the suscep-
tibility of the two subsets in such PHA-prestimulated
PBMCs, where X4 HIV-1 showed more rapid replication
kinetics. These results suggested the possible produc-
tion of soluble factor(s) in the conditioned medium of
PBMC cultures on stimulation with PHA. In fact, Th2
cytokine was apparently secreted from the CD38 sub-
set on stimulation with PHA as well as anti-CD3 MAb.
Time course analysis revealed that the production of Th2
cytokine was transient during the first 3 days of culture
(data not shown). In contrast, the CD38 subset showed
a tendency to produce higher levels of Th1 cytokine than
the CD38 subset following stimulation in many prepa-
rations. Therefore, IL-4 in place of PHA was used as a
stimulant and found to contribute to the efficient produc-
tion of X4 HIV-1 in the CD38 subset. This cytokine did
not significantly affect HIV-1 production in the CD38
subset. However, the slight effect of the conditioned
medium from the CD38 subset on the production of X4
HIV-1 in the CD38 subset suggests the presence of an
additional soluble factor(s) in the conditioned medium.
Flow cytometry showed similar expression levels of
CD4 as well as CXCR4 on the surface of both subsets
after PHA or IL-4 stimulation for 3 days. In fact, adsorp-
tion rates of LAI were also similar between the subsets
before (Horikoshi et al., 2001) and after stimulation with
PHA or IL-4 (data not shown). In addition, the expression
of IL-4 receptor did not differ significantly between the
subsets. Thus, IL-4 cytokine may be responsible for the
efficient production of HIV-1, which could be due to up-
regulation at a certain stage of the viral life cycle, prob-
ably after adsorption. For understanding the mechanism,
we need further study to detect an IL-4-associated fac-
tor(s) responsible for this amplification only in CD38
subset.
There was a report of stronger expression of CXCR4 in
the Th2 than Th1 subset (Suzuki et al., 1999). In that
study, the cells were used only after differentiation into
Th1 or Th2 cells by stimulation with anti-CD3/IL-2/IL-12
or anti-CD3/IL-2/IL-4, respectively, long term (8 days)
before HIV-1 infection. It was concluded that such Th2
and Th1 differentiated cells showed greater susceptibil-
ity to X4 and R5 HIV-1 due to a slight upregulation of
CXCR4 and CCR5, respectively. On the other hand, we
found a clear difference in the susceptibility to X4 HIV-1
between resting CD38 and CD38 subsets on infection
before stimulation. Thus, the CD38 cells even in the
resting stage comprise a specific cell population that can
preferentially secrete the Th2 cytokine on stimulation
with PHA or anti-CD3 MAb. Such an endogenously se-
creted Th2 cytokine could contribute to efficient replica-
tion of X4 HIV-1.
The presence of other factors contributing to the inhi-
bition of HIV-1 replication, which may be secreted from
the cells during PHA treatment, should also be consid-
ered. Cytokines such as IFN- could be candidates for
the factor inhibiting HIV-1 replication, as reported (Galli
et al., 1998). More of IFN- was present in the culture of
the CD38 than CD38 subset after infection followed by
PHA stimulation. Since the replication rate of R5 HIV-1
was higher in the CD38 than CD38 subset (Horikoshi
et al., 2001), further study is necessary to clarify the role
FIG. 6. No apparent difference in the surface expression levels of HIV-1 receptors CD4 and CXCR4 between CD38 subsets after PHA or IL-4
stimulation. CD4CD38 and CD4CD38 subsets after treatment with PHA (A) or IL-4 (B) for 3 days were subjected to flow cytometry with anti-CXCR4
or anti-CD4 MAb (O). The profiles with control IgG are shown by (---). Cells in A and B were stained by indirect and direct methods, respectively.
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of these cytokines in controlling the replication of X4 and
R5 HIV-1s.
It has been documented that there is a daily infected
vs healthy CD4 T cell replacement war occurring in the
patients, so that infected, dying cells continually are
replaced (Ho et al., 1995; Wei et al., 1995; Perelson et al.,
1996). Considering that the CD4CD38 subset showed
greater susceptibility to X4 HIV-1 infection, this subset
may represent newly generated CD4 T cells which can
secrete Th2 cytokine and efficient infection of this subset
by HIV-1 with X4 tropism can synergistically accelerate
the course of HIV-1 disease.
MATERIALS AND METHODS
Viruses
Culture fluid of MOLT-4 cells persistently infected with
LAI was used as the prototypic X4-type HIV-1. Two pri-
mary X4-type HIV-1 isolates were also used: 0-4-26 from
a Japanese asymptomatic carrier (homosexual; CD4
cells, 322/mm3) and 17-3-6 from a Japanese AIDS patient
(hemophiliac; CD4 cells, 77/mm3). HIV-1 particles in the
conditioned media for primary isolates as well as LAI
were pelleted by centrifugation at 100,000 g for 30 min
and then suspended in RPMI 1640 supplemented with
10% fetal bovine serum, as previously described (Hori-
koshi et al., 2001).
Preparation of normal peripheral blood-derived T cell
subsets
Isolation of the whole CD4 T cell fraction from pe-
ripheral blood was performed by depletion of non-CD4
T cells. First, PBMCs were obtained by centrifugation
over Ficoll–Paque (Pharmacia Biotech, Uppsala, Swe-
den). For depletion of B cells, monocytes, natural killer
cells, CD8 T cells, dendritic cells, early erythroid cells,
platelets, and basophils from PBMCs, such cells in the
PBMCs were indirectly magnetically labeled using a
cocktail of hapten-conjugated CD8, CD11b, CD16, CD19,
CD36, and CD56 antibodies and MACS Microbeads cou-
pled to an anti-hapten MAb (Miltenyi Biotec, Gladbach,
Germany). The magnetically labeled cells are depleted
by retaining them on a MACS column in the magnetic
field of a MACS separator (Miltenyi Biotec). Subse-
quently, to obtain resting T cells, cells were labeled with
CD25 MAb (anti-IL-2R; Becton-Dickinson Immunocytom-
etry Systems) and magnetically labeled with goat anti-
mouse IgG Microbeads (Miltenyi Biotec) and separated
on a column, as above. The resting CD4 T cell fraction
was further separated into two T cell subsets (CD38
and CD38) by panning with a MAb to CD38 (Leu-17;
Becton-Dickinson Immunocytometry Systems) followed
by addition of goat anti-mouse IgG Microbeads (Miltenyi
Biotec). These cells were simulated with PHA at 2 g/ml
or IL-4 at 10 ng/ml before or after HIV-1 infection, as
described below. Also, the cells were stimulated with
PHA at 2 g/ml or with anti-CD3 by culturing the cells in
microplates for measuring cytokine production in individ-
ual subsets. For the stimulation with anti-CD3, micro-
plates, coated with anti-CD3 MAb (PharMingen) at 10
g/ml (Baroja et al., 1989) for 12 h, followed by washing
three times, were used.
HIV-1 infection
HIV-1 infection studies were performed by three pro-
tocols. First, HIV-1 infection of PBMC-derived resting
CD4 T cell subsets prepared as above was performed
by adsorption with HIV-1 for 1 h at 37°C. After extensive
washing, cells at 2  106/ml were cultured in the pres-
ence of 2 g/ml PHA and 50 u/ml IL-2 for 3 days. Second,
the same PBMC-derived resting CD4 T cell subsets
were pretreated with PHA at 2 g/ml for 3 days. These
stimulated T cell subsets were similarly infected with
HIV-1 and cultured at 1  106/ml in medium containing
50 u/ml IL-2. Third, in place of PHA stimulation, the
resting T cell subsets after HIV-1 infection as above were
also treated with the conditioned medium of the T cell
cultures stimulated with 2 g/ml PHA for 3 days or 10
ng/ml IL-4 and cultured at 1  106/ml in medium con-
taining 50 u/ml IL-2.
These cells were adjusted to 1  106/ml every 3 days
and further cultured in medium containing 50 u/ml of IL-2.
Viable cells were enumerated by the trypan blue exclu-
sion assay.
Evaluation of T cell subsets for cell susceptibility to
HIV-1 infection
HIV-1 susceptibility was determined from levels of
HIV-1 production in conditioned media sequentially ob-
tained from infected cells and from levels of HIV-1 anti-
gen expression on the surface of infected cells at a late
stage of infection. Virus production was measured by
HIV-1 p24 antigen-capture ELISA (ZeptoMetrix Corp.,
Buffalo, NY). Viral antigen expression on the infected
cells was measured by flow cytometry using the serum
from an HIV-1-seropositive individual, as described be-
low.
ELISA for cytokine production levels
The concentrations of IL-4 and IFN- in the culture
supernatants from T cell subsets were measured with an
ELISA kit (high-sensitivity interleukin-4 human, ELISA
system and high-sensitivity interferon-gamma human,
ELISA system, respectively; Amersham Pharmacia Bio-
tech, Uppsala, Sweden).
Flow cytometry
For single cell staining by indirect flow cytometry,
mock- or HIV-1-infected cells were incubated for 30 min
100 HORIKOSHI ET AL.
at 4°C with a 500-fold dilution (immunofluorescence titer,
1:4000) of serum from an HIV-1-seropositive individual as
the polyclonal anti-HIV-1. In negative controls, the same
amount of serum (500-fold dilution) from one seronega-
tive healthy donor was used. Cells were washed with
phosphate-buffered saline (PBS) and then further re-
acted with FITC-conjugated rabbit anti-human IgG
(DAKO). Also, the cells were reacted with anti-CD4 MAb
(Becton-Dickinson Immunocytometry Systems) or anti-
CXCR4 MAb (PharMingen) and stained with FITC-conju-
gated rabbit anti-mouse IgG (DAKO). In addition, the
following antibodies were used for direct flow cytometry:
PE-conjugated MAbs to CD4 (Becton-Dickinson Immu-
nocytometry Systems) and to CXCR4 (PharMingen). In
negative controls for direct flow cytometry, the same
amounts of PE-conjugated normal mouse IgG1 (Becton-
Dickinson Immunocytometry Systems) and IgG2a
(PharMingen) were used.
To analyze the IL-4 receptor expression, cells were
reacted with biotin-IL-4, followed by the FITC-avidine in
the IL-4 receptor detection kit (Biotinylated Human IL-4;
Genzyme-Techne). In double staining, cells were first
reacted with FITC-IL-4 as above and then with PE-con-
jugated anti-CD38 MAb (Becton-Dickinson Immunocy-
tometry Systems).
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